This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutStorage and handlingVial sizes and NDC numbersBiochemical composition and manufacturingDosing & Infusion RatesDosing & 
Infusion Rates
CIDPDosing and administrationInfusion rate chartInfusion rate calculatorPIDosing and administrationInfusion rate chartInfusion rate calculatorcITPDosing and administrationInfusion rate chartInfusion rate calculator
EfficacyEfficacyCIDPStudy designINCAT responder ratesSupporting efficacy endpointsRescue dosingPatient profilesPIStudy designsPrimary endpoint, supporting efficacy endpoints, and safety assessmentsPatient profilescITPStudy design, primary endpoint, and supporting efficacy endpointsSafety & TolerabilitySafety & TolerabilityCIDPPIcITPSupportSupportMaterialsVideosCIDP Warranty ProgramPfizer PANZYGA Co-Pay Program for patientsPfizer IGuideTMIg Companion patient mobile appFrequently asked questionsRequest a representative
Prescribing Information, including BOXED WARNINGIndicationsImportant Safety Information
Dosing & Infusion RatesPI

PI
dosing and administration

PI
infusion rate chart

PI
infusion rate calculator

Tab Number 4

Tab Number 5

PANZYGA has the only FDA-approved infusion rate of 14 mg/kg/min for PI, as tolerated190% of patients (19 of 21) with PI in an extension study achieved the maximum infusion rate of 14 mg/kg/min1*
  • The initial infusion rate should be maintained for 30 minutes. Following the initial infusion, and if tolerated, the infusion rate may be gradually increased every 15-30 minutes, as tolerated, to the maximum infusion rate of 14 mg/kg/min (0.14 mL/kg/min)1† 
19 of the 21 enrolled patients received PANZYGA up to the maximum allowed infusion rate of 14 mg/kg/min.Significant differences in the half-life of IgG among patients with PI may necessitate the dose and frequency of immunoglobulin therapy to vary from patient to patient. Determine the proper dose and frequency by monitoring the clinical response. Adjust dose over time to achieve the desired trough levels of IgG and clinical responses.Infusion times under 1 hr 30 min for doses 40 g if maximum infusion rate is tolerated1Example ramp-up schedule for a patient with PI
  • PANZYGA should be started at 1 mg/kg/min and continued at the infusion rates stated here, if tolerated1
  • The example shown above illustrates a ramp-up schedule for an 80-kg patient with PI following a ramp-up of 1, 4, 8, and 14 mg/kg/min
  • For patients at risk of renal dysfunction or thromboembolic events, administer PANZYGA at the minimum infusion rate practicable. Do not exceed 3.3 mg/kg/min (0.033 mL/kg/min). Discontinue if renal function deteriorates1
Reference:Panzyga. Prescribing information. Octapharma USA Inc.; 2021.
The PANZYGA infusion rate chart below will help you calculate the appropriate infusion rate for a patient with PI
  •  300 mg/kg to 600 mg/kg of body weight (3-6 mL/kg) administered every 3 to 4 weeks1
  • The initial infusion rate should be maintained for 30 minutes. Following the initial infusion, and if tolerated, the infusion rate may be gradually increased every 15 to 30 minutes, as tolerated, to a maximum of 14 mg/kg/min (0.14 mL/kg/min)1
Download the PANZYGA PI Infusion Rate ChartLoading
Reference:Panzyga. Prescribing information. Octapharma USA Inc.; 2021.
Step 1: Choose an indication
With this calculator, you can determine the:
  • infusion ramp-up rate to program into an IV infusion pump
  • estimated time to complete the infusion
Choose an indication:
Step 2: Enter the patient’s body weight and PANZYGA dose for this infusion

Adult patient with CIDP

One field from each section below is required.
Enter patient’s body weight
  lb
OR
  kg
ANDEnter patient’s PANZYGA dose for this infusion
   g
OR
  mL
Calculated answer: Recommended ramp-up infusion rates

Adult patient with CIDP

Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.02 mL/kg/min
(2 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.thirdInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.fourthInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.12 mL/kg/min
(12 mg/kg/min)

{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} is between {{minInfusionTime}} - {{maxInfusionTime}}

(if the rates above are tolerated by the patient)

Step 2: Enter patient's body weight and PANZYGA dose for this infusion

Patient 2 years or older with PI

One field from each section below is required.
Enter patient’s body weight
  lb
OR
  kg
ANDEnter patient’s PANZYGA dose for this infusion
   g
OR
  mL
Calculated answer: Recommended ramp-up infusion rates

Patient 2 years or older with PI

Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.thirdInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.14 mL/kg/min
(14 mg/kg/min)

{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} is between {{minInfusionTime}} - {{maxInfusionTime}}

(if the rates above are tolerated by the patient)

Step 2: Enter the patient’s body weight and PANZYGA dose for this infusion

Adult patient with cITP

One field from each section below is required.

Enter patient’s body weight

  lb
OR
  kg
ANDEnter patient’s PANZYGA dose for this infusion
   g
OR
  mL
Calculated answer: Recommended ramp-up infusion rates

Adult patient with cITP

Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} is between {{minInfusionTime}} - {{maxInfusionTime}}

(if the rates above are tolerated by the patient)

Dosing & Infusion Rates PI efficacy data for PANZYGA Review now Loading PI safety and tolerability data for PANZYGA Review data Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-PAN-USA-0828
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-PAN-USA-0594
INDICATIONS AND USAGE PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE IMPORTANT SAFETY INFORMATION
  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
Contraindications PANZYGA is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity. Warnings and Precautions Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA. Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). Monitor blood pressure prior to, during, and following PANZYGA infusion. Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload. PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions PI – The most common adverse reactions (>5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain. cITP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia. CIDP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, dermatitis, and blood pressure increase. The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. PANZYGA® is a registered trademark of Octapharma AG. Please click here for Full Prescribing Information, including BOXED WARNING. Helix ImageINDICATIONS 
AND USAGE
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.